European Archives - Page 533 of 1129 - European Medical Journal

Neurofibromatosis Type 1: Burden of Disease in Patients with Plexiform Neurofibromas

NF1 is an autosomal dominant disorder, arising from a mutation in the gene that encodes neurofibromin. It is a tumour-predisposing…

Management and Multi-specialty Approach in the Evolving Treatment Landscape of Neurofibromatosis Type 1 Plexiform Neurofibromas

Neurofibromatosis Type 1 (NF1) is a rare disease, occurring in approximately 1 in 3,000 people. Among the numerous manifestations…

Aficamten: A New Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy

REDWOOD-HCM was a multicentre, randomised, placebo-controlled, double-blind, dose-finding clinical trial of aficamten in patients with symptomatic oHCM on background medical therapy.

Automated Echocardiography Analysis: Expanding Access and Saving Time

December marks the launch of Us2.ai’s automated cardiac analysis platform1 as a cloud-based service on the EchoNous Kosmos device…

Identifying Common Biomarkers Between COVID-19 and Commonly Associated Comorbidities

The recent COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, since its…

Current Therapy for Homozygous Familial Hypercholesterolaemia

Homozygous familial hypercholesterolaemia (HoFH) is a rare and aggressive disorder, resulting from the inheritance of mutations in the two alleles of genes regulating the low-density lipoprotein receptor (LDL-R) function.

Risk Factors and Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis: An Update

The therapeutic technique of endoscopic retrograde cholangiopancreatography (ERCP) has evolved as a therapeutic endoscopic technique for…

Cefixime-Induced Hepatitis: A Case Report and Review of Literature

Cephalosporins, a family of bactericidal antibiotics, have side effects like penicillin due to the similarity in their basic structure…

The biotech boom: fad or forever?

Biotechs have stood as agile hubs for drug discovery, but now they are being coveted by investors.

Standing out in a crowd of digital content

The amount of digital content being created for healthcare professionals has grown exponentially. Medical affairs teams must find a way to cut through the noise with their communications